News

Get the latest from Biologics

We invite you to learn more about our work. Check out our organization’s recent news, and browse our press releases to see what we’ve been doing. You can also check out upcoming events in which we’ll be participating or read more about our how we give back to our community.

Biologics, Inc. Grows Team Over 400 Percent in Five Years, Expands into New Corporate Office

CARY, NC – July 7, 2015 – After five years of tremendous growth, Biologics, Inc. is pleased to announce the company’s expansion into a new 76,000 square foot corporate office building located in Cary, North Carolina. This is the first in a series of planned expansion projects for the company. “Our growth and facilities expansion is… Read More

Smith Named 2015 Next-Generation Pharmacist, Specialty Pharmacy

PLAINSBORO, N.J. (June 10, 2015) — Parata Systems and Pharmacy Times are pleased to announce the finalists for the 2015 Next-Generation Pharmacist® awards. Now in its sixth year, the Next-Generation Pharmacist awards honor pharmacists, technicians, student pharmacists and industry advocates who are defining the future of the industry. Pharmacy’s leaders will come together to recogniz… Read More

Biologics, Inc. Secures Over $29 Million in Copay Assistance for Cancer Patients in 2014

CARY, NC — April 13, 2015 — Biologics, Inc. is pleased to announce that its Patient Access Services team secured over $29 million in copay assistance for patients diagnosed with cancer in 2014. One in four of Biologics’ patients request financial assistance to help them afford their medications. Due to the high costs associated with many cancer drugs,… Read More

Biologics selected as limited distribution network partner for Farydak® (panobinostat)

CARY, NC — March 4, 2015 — Biologics, an integrated oncology services company, is pleased to be selected by Novartis as a limited distribution network partner of Farydak® (panobinostat). Farydak was approved by the U.S. Food and Drug Administration on February 23, 2015 in combination with bortezomib and dexamethasone for the treatment of patients wit… Read More

Bayer has selected Biologics, Inc. as a limited distribution network provider for NEXAVAR® (sorafenib) and STIVARGA® (regorafenib)

CARY, NC — February 20, 2015 — Biologics, an integrated oncology services company, is pleased to announce that Bayer HealthCare Pharmaceuticals, Inc. has selected the company to be a limited distribution network provider for two leading oncology medications, NEXAVAR® (sorafenib) and STIVARGA® (regorafenib). NEXAVAR is approved by the U.S. Food and Drug Administration (FDA) for… Read More

Lenvima™ (lenvatinib) approved for radioactive iodine-refractory differentiated thyroid cancer, available through Biologics, Inc.

CARY, NC — February 13, 2015 — Biologics, Inc. an integrated oncology services company, is pleased to announce that Eisai Inc. has selected Biologics to be a specialty pharmacy provider within its limited distribution network for Lenvima™ (lenvatinib). Lenvima was approved by the U.S. Food and Drug Administration on February 13, 2015 for the treatment… Read More

Ibrance® (palbociclib) approved for ER+, HER2- advanced breast cancer, available immediately at Biologics, Inc.

CARY, NC — February 5, 2015 — Biologics, an integrated oncology services company, is pleased to announce that Biologics has been selected as a specialty pharmacy authorized to dispense Ibrance (palbociclib). Ibrance was approved by the U.S. Food and Drug Administration on February 3, 2015 to be used in combination with letrozole for the treatment… Read More

Biologics, Inc. is pleased to announce the continued clinical support of oncology therapies for SilverScript Prescription Drug Plan

CARY, NC — January 20, 2015 —Biologics, an integrated oncology services company, will continue to help members of the SilverScript Prescription Drug Plan in accessing and affording their oncology therapies.  Our clinical expertise in cancer treatments combined with our broad access to both limited and exclusive distribution therapies will insure both access to medications and… Read More

Biologics, Inc. Introduces Maraya Thorland as Director, Care Integration Services

CARY, NC — January 9, 2015 — Biologics, an integrated oncology services company, has announced the addition of Maraya Thorland as Director, Care Integration Services. In this role, Thorland will be responsible for the development, implementation and ongoing management of provider contracting and claims review, as well as case and utilization management services in support… Read More

LYNPARZA™ (olaparib) approved for the treatment of advanced relapsed ovarian cancer in patients with germline BRCA mutations, available exclusively at Biologics, Inc.

CARY, NC — December 19, 2014 — Biologics, an integrated oncology services company, is pleased to announce that AstraZeneca has selected the company to be the exclusive distribution network provider for LYNPARZA (olaparib). LYNPARZA was approved by the U.S. Food and Drug Administration on December 19, 2014  as the first monotherapy for patients with deleterious… Read More